Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia

Key Points

• The aim is to investigate the effects of evinacumab on triglyceride levels in individuals with high and severe hypertriglyceridemia.
• Conducted a randomized trial involving subjects with high and severe hypertriglyceridemia.
• Administered evinacumab to evaluate its impact on triglyceride reduction.
• Measured baseline and follow-up triglyceride levels for assessment.
• Evinacumab led to a significant reduction in triglyceride levels, with an average decrease of X mg/dL (exact values not provided).
• The intervention showed a strong effect size (exact metrics not stated).
• P-value was significant, indicating meaningful clinical change.